Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MRGPRX1 | Q96LB2 | 7/20 | 0.51 |
| ▸ | HRH1 | P35367 | 1/20 | 0.51 |
| ▸ | KIT | P10721 | 1/20 | 0.45 |
| ▸ | TLR4 | O00206 | 1/20 | 0.44 |
| ▸ | TSPO | P30536 | 1/20 | 0.41 |
| ▸ | BRAF | P15056 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.38 |
| ▸ | FEN1 | P39748 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL391647 | 0.85 | MRGPRX1 (0.44) | MRGPRX1HRH1KITTLR4TSPO | |
| SCHEMBL12407120 | 0.83 | FKBP1A (0.53) | MRGPRX1HRH1KMT2A | |
| SCHEMBL14830633 | 0.83 | KIT (0.52) | MRGPRX1HRH1KITTSPOKMT2A | |
| SCHEMBL19050690 | 0.82 | MRGPRX1 (0.41) | MRGPRX1HRH1KITTLR4TSPO | |
| SCHEMBL13855804 | 0.81 | — | — | |
| SCHEMBL19050669 | 0.80 | MRGPRX1 (0.40) | MRGPRX1HRH1TLR4BRAFKMT2A | |
| SCHEMBL4134490 | 0.79 | MAP2K1 (0.54) | MRGPRX1HRH1KITBRAF | |
| SCHEMBL19050673 | 0.79 | MRGPRX1 (0.40) | MRGPRX1HRH1TLR4BRAFKMT2A | |
| SCHEMBL9284438 | 0.79 | BRAF (0.48) | MRGPRX1HRH1BRAF | |
| SCHEMBL19050657 | 0.79 | MEN1 (0.47) | MRGPRX1HRH1TLR4BRAFKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7973069-B2 | Methods for treating hepatitis C | PTC THERAPEUTICS, INC. (US) | 2011-07-05 | — | — | US | disclosed |
| US-20100305100-A1 | METHODS FOR TREATING HEPATITIS C | PTC THERAPEUTICS, INC. (US) | 2010-12-02 | — | — | US | disclosed |
| US-20100292187-A1 | METHODS FOR TREATING HEPATITIS C | PTC THERAPEUTICS, INC. (US) | 2010-11-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100292187-A1 | METHODS FOR TREATING HEPATITIS C | HAVCR2, EIF2AK2, MAVS | MRGPRX1 1873/4885HRH1 2713/4885KIT 1858/4885 |
| US-20100305100-A1 | METHODS FOR TREATING HEPATITIS C | HAVCR2, EIF2AK2, MAVS | MRGPRX1 1873/4885HRH1 2713/4885KIT 1858/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.